دورية أكاديمية
CGRP receptor antagonists for migraine. Are they also AMY 1 receptor antagonists?
| العنوان: | CGRP receptor antagonists for migraine. Are they also AMY |
|---|---|
| المؤلفون: | Garelja ML; Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand., Walker CS; School of Biological Sciences, University of Auckland, Auckland, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand., Hay DL; Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand. |
| المصدر: | British journal of pharmacology [Br J Pharmacol] 2022 Feb; Vol. 179 (3), pp. 454-459. Date of Electronic Publication: 2021 Jun 24. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Wiley Original Publication: London, Macmillian Journals Ltd. |
| مواضيع طبية MeSH: | Migraine Disorders*/drug therapy , Migraine Disorders*/metabolism , Receptors, Calcitonin Gene-Related Peptide*/metabolism, Calcitonin Gene-Related Peptide ; Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Calcitonin Receptor-Like Protein ; Humans |
| مستخلص: | The development of several drugs that target the calcitonin gene-related peptide (CGRP) system has been a major breakthrough in the pharmacological management of migraine. These are divided into two major classes, antibodies which bind to the CGRP peptide, preventing it from activating CGRP receptors and receptor antagonists. Within the receptor antagonist class, there are two mechanisms of action, small molecule receptor antagonists and an antibody antagonist. This mini-review considers the pharmacology of these receptor targeted antagonist drugs at the CGRP receptor and closely related AMY (© 2021 The British Pharmacological Society.) |
| References: | Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP collaborators. (2019). The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176(Suppl 1), S21-S141. https://doi.org/10.1111/bph.14748. Ankrom, W., Bondiskey, P., Li, C. C., Palcza, J., Liu, W., Dockendorf, M. F., Matthews, C., Panebianco, D., Reynders, T., Wagner, J. A., Jakate, A., Mesens, S., Kraft, W. K., & Marcantonio, E. E. (2020). Ubrogepant is not associated with clinically meaningful elevations of alanine aminotransferase in healthy adult males. Clinical and Translational Science, 13(3), 462-472. https://doi.org/10.1111/cts.12728. Bhakta, M., Vuong, T., Taura, T., Wilson, D. S., Stratton, J. R., & Mackenzie, K. D. (2021). Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia, 41(5), 499-514. https://doi.org/10.1177/0333102420983282. Boinpally, R., Jakate, A., Butler, M., Borbridge, L., & Periclou, A. (2021). Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: Results from an open-label, phase 1 trial. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.916. Bower, R. L., Yule, L., Rees, T. A., Deganutti, G., Hendrikse, E. R., Harris, P. W. R., Kowalczyk, R., Ridgway, Z., Wong, A. G., Swierkula, K., Raleigh, D. P., Pioszak, A. A., Brimble, M. A., Reynolds, C. A., Walker, C. S., & Hay, D. L. (2018). Molecular signature for receptor engagement in the metabolic peptide hormone amylin. ACS Pharmacology & Translational Science, 1(1), 32-49. https://doi.org/10.1021/acsptsci.8b00002. Choksi, T., Hay, D. L., Legon, S., Poyner, D. R., Hagner, S., Bloom, S. R., & Smith, D. M. (2002). Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. British Journal of Pharmacology, 136(5), 784-792. Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999). Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular Pharmacology, 56(1), 235-242. https://doi.org/10.1124/mol.56.1.235. de Hoon, J., Van Hecken, A., Vandermeulen, C., Yan, L., Smith, B., Chen, J. S., Bautista, E., Hamilton, L., Waksman, J., Vu, T., & Vargas, G. (2018). Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clinical Pharmacology and Therapeutics, 103(5), 815-825. https://doi.org/10.1002/cpt.799. Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018). CGRP as the target of new migraine therapies-Successful translation from bench to clinic. Nature Reviews. Neurology, 14(6), 338-350. https://doi.org/10.1038/s41582-018-0003-1. Edvinsson, L., & Linde, M. (2012). CGRP antagonists for the treatment of migraine:Rationale and clinical data. Clinical Investigation, 2(1), 73-88. https://doi.org/10.4155/cli.11.168. Garces, F., Mohr, C., Zhang, L., Huang, C. S., Chen, Q., King, C., Xu, C., & Wang, Z. (2020). Molecular insight into recognition of the CGRPR complex by migraine prevention therapy Aimovig (Erenumab). Cell Reports, 30(6), 1714-1723.e6. https://doi.org/10.1016/j.celrep.2020.01.029. Ghanizada, H., Al-Karagholi, M. A., Walker, C. S., Arngrim, N., Rees, T., Petersen, J., Siow, A., Morch-Rasmussen, M., Tan, S., O'Carroll, S. J., Harris, P., Skovgaard, L. T., Jorgensen, N. R., Brimble, M., Waite, J. S., Rea, B. J., Sowers, L. P., Russo, A. F., Hay, D. L., & Ashina, M. (2021). Amylin analog pramlintide induces migraine-like attacks in patients. Annals of Neurology, 89, 1157-1171. https://doi.org/10.1002/ana.26072. Gingell, J. J., Hendrikse, E. R., & Hay, D. L. (2019). New insights into the regulation of CGRP-family receptors. Trends in Pharmacological Sciences, 40(1), 71-83. https://doi.org/10.1016/j.tips.2018.11.005. Gingell, J. J., Rees, T. A., Hendrikse, E. R., Siow, A., Rennison, D., Scotter, J., Harris, P. W. R., Brimble, M. A., Walker, C. S., & Hay, D. L. (2020). Distinct patterns of internalization of different calcitonin gene-related peptide receptors. ACS Pharmacology & Translational Science, 3(2), 296-304. https://doi.org/10.1021/acsptsci.9b00089. Han, T. H., Blanchard, R. L., Palcza, J., Martucci, A., Miller-Stein, C. M., Gutierrez, M., Panebianco, D., Rippley, R. K., Lines, C., & Murphy, M. G. (2010). The dose proportionality of telcagepant after administration of single oral and intravenous doses in healthy adult subjects. Archives of Drug Information, 3(4), 55-62. https://doi.org/10.1111/j.1753-5174.2010.00031.x. Hargreaves, R., & Olesen, J. (2019). Calcitonin gene-related peptide modulators-The history and renaissance of a new migraine drug class. Headache, 59(6), 951-970. https://doi.org/10.1111/head.13510. Hay, D. L., Christopoulos, G., Christopoulos, A., Poyner, D. R., & Sexton, P. M. (2005). Pharmacological discrimination of calcitonin receptor: Receptor activity-modifying protein complexes. Molecular Pharmacology, 67(5), 1655-1665. https://doi.org/10.1124/mol.104.008615. Hay, D. L., Christopoulos, G., Christopoulos, A., & Sexton, P. M. (2006). Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-d ibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny l) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-The role of receptor activity modifying protein 1. Molecular Pharmacology, 70(6), 1984-1991. https://doi.org/10.1124/mol.106.027953. Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018). Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. British Journal of Pharmacology, 175(1), 3-17. https://doi.org/10.1111/bph.14075. Hay, D. L., & Walker, C. S. (2017). CGRP and its receptors. Headache, 57(4), 625-636. https://doi.org/10.1111/head.13064. Hendrikse, E. R., Bower, R. L., Hay, D. L., & Walker, C. S. (2019). Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia, 39(3), 403-419. https://doi.org/10.1177/0333102418765787. Hershey, J. C., Corcoran, H. A., Baskin, E. P., Salvatore, C. A., Mosser, S., Williams, T. M., Koblan, K. S., Hargreaves, R. J., & Kane, S. A. (2005). Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regulatory Peptides, 127(1-3), 71-77. https://doi.org/10.1016/j.regpep.2004.10.010. Iovino, M., Feifel, U., Yong, C. L., Wolters, J. M., & Wallenstein, G. (2004). Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia, 24(8), 645-656. https://doi.org/10.1111/j.1468-2982.2004.00726.x. Kenakin, T. (2009). Biased agonism. F1000 Biology Reports, 1(11), 87. https://doi.org/10.3410/B1-87. Luo, G., Chen, L., Conway, C. M., Denton, R., Keavy, D., Signor, L., Kostich, W., Lentz, K. A., Santone, K. S., Schartman, R., Browning, M., Tong, G., Houston, J. G., Dubowchik, G. M., & Macor, J. E. (2012). Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyri din-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. Journal of Medicinal Chemistry, 55(23), 10644-10651. https://doi.org/10.1021/jm3013147. Mallee, J. J., Salvatore, C. A., LeBourdelles, B., Oliver, K. R., Longmore, J., Koblan, K. S., & Kane, S. A. (2002). Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. The Journal of Biological Chemistry, 277(16), 14294-14298. https://doi.org/10.1074/jbc.M109661200. Miller, P. S., Barwell, J., Poyner, D. R., Wigglesworth, M. J., Garland, S. L., & Donnelly, D. (2010). Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochemical and Biophysical Research Communications, 391(1), 437-442. https://doi.org/10.1016/j.bbrc.2009.11.076. Moore, E., Fraley, M. E., Bell, I. M., Burgey, C. S., White, R. B., Li, C. C., Regan, C. P., Danziger, A., Stranieri Michener, M., Hostetler, E., Banerjee, P., & Salvatore, C. (2020). Characterization of ubrogepant: A potent and selective antagonist of the human calcitonin gene-related peptide receptor. The Journal of Pharmacology and Experimental Therapeutics, 373(1), 160-166. https://doi.org/10.1124/jpet.119.261065. Moore, E. L., Gingell, J. J., Kane, S. A., Hay, D. L., & Salvatore, C. A. (2010). Mapping the CGRP receptor ligand binding domain: Tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. Biochemical and Biophysical Research Communications, 394(1), 141-145. https://doi.org/10.1016/j.bbrc.2010.02.131. Moore, E. L., & Salvatore, C. A. (2012). Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. British Journal of Pharmacology, 166(1), 66-78. https://doi.org/10.1111/j.1476-5381.2011.01633.x. Pan, K. S., Siow, A., Hay, D. L., & Walker, C. S. (2020). Antagonism of CGRP signaling by rimegepant at two receptors. Frontiers in Pharmacology, 11(1240). https://doi.org/10.3389/fphar.2020.01240. Salvatore, C. A., Hershey, J. C., Corcoran, H. A., Fay, J. F., Johnston, V. K., Moore, E. L., Mosser, S. D., Burgey, C. S., Paone, D. V., Shaw, A. W., Graham, S. L., Vacca, J. P., Williams, T. M., Koblan, K. S., & Kane, S. A. (2008). Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. The Journal of Pharmacology and Experimental Therapeutics, 324(2), 416-421. https://doi.org/10.1124/jpet.107.130344. Salvatore, C. A., Moore, E. L., Calamari, A., Cook, J. J., Michener, M. S., O'Malley, S., Miller, P. J., Sur, C., Williams, D. L. Jr., Zeng, Z., Danziger, A., Lynch, J. J., Regan, C. P., Fay, J. F., Tang, Y. S., Li, C. C., Pudvah, N. T., White, R. B., Bell, I. M., … Kane, S. A. (2010). Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. The Journal of Pharmacology and Experimental Therapeutics, 333(1), 152-160. https://doi.org/10.1124/jpet.109.163816. Shi, L., Lehto, S. G., Zhu, D. X. D., Sun, H., Zhang, J., Smith, B. P., Immke, D. C., Wild, K. D., & Xu, C. (2016). Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. Journal of Pharmacology and Experimental Therapeutics, 356(1), 223-231. https://doi.org/10.1124/jpet.115.227793. Walker, C. S., Eftekhari, S., Bower, R. L., Wilderman, A., Insel, P. A., Edvinsson, L., Waldvogel, H. J., Jamaluddin, M. A., Russo, A. F., & Hay, D. L. (2015). A second trigeminal CGRP receptor: Function and expression of the AMY1 receptor. Annals of Clinical Translational Neurology, 2(6), 595-608. https://doi.org/10.1002/acn3.197. Walker, C. S., Raddant, A. C., Woolley, M. J., Russo, A. F., & Hay, D. L. (2018). CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured. Cephalalgia, 38(3), 437-451. https://doi.org/10.1177/0333102417691762. Wyllie, D. J., & Chen, P. E. (2007). Taking the time to study competitive antagonism. British Journal of Pharmacology, 150(5), 541-551. https://doi.org/10.1038/sj.bjp.0706997. |
| فهرسة مساهمة: | Keywords: AMY1; CGRP; RAMP1; amylin; migraine |
| المشرفين على المادة: | 0 (Calcitonin Gene-Related Peptide Receptor Antagonists) 0 (Calcitonin Receptor-Like Protein) 0 (Receptors, Calcitonin Gene-Related Peptide) JHB2QIZ69Z (Calcitonin Gene-Related Peptide) |
| تواريخ الأحداث: | Date Created: 20210602 Date Completed: 20220413 Latest Revision: 20220413 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/bph.15585 |
| PMID: | 34076887 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1476-5381 |
|---|---|
| DOI: | 10.1111/bph.15585 |